The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 20, 2021

Filed:

Dec. 30, 2016
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Christopher Sweeney, Waban, MA (US);

Philip Kantoff, New York, NY (US);

Gwo-Shu Mary Lee, Newton, MA (US);

Kazumasa Komura, New York, NY (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/4166 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/686 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61P 35/00 (2018.01); C12N 5/0693 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/686 (2013.01); G01N 33/57434 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/166 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.


Find Patent Forward Citations

Loading…